Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several safety/interaction claims are broadly aligned with labeled warnings (bleeding; fish/shellfish allergy; general monitoring with concomitant antithrombotic agents). However, multiple claims are unsupported or inaccurately specific relative to the provided label excerpt (e.g., pancreatitis risk statement, contraindications in pregnancy/breastfeeding, fish/shellfish allergy certainty, and specific drug-subclass risks for diabetes agents, statins, and hypotension with antihypertensives).
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) may increase the risk of bleeding when taken with blood thinners such as warfarin.
Label 5.3 states incidence of bleeding is greater in patients receiving concomitant antithrombotic medications such as aspirin, clopidogrel, or warfarin; and Label 7.1 advises monitoring patients receiving VASCEPA with concomitant anticoagulants/antiplatelet agents for bleeding.
Patients taking blood thinners while using Vascepa should be closely monitored by their healthcare provider.
Label 7.1: Monitor patients receiving VASCEPA and concomitant anticoagulants and/or antiplatelet agents for bleeding.
Taking Vascepa with fish oil supplements may increase the risk of bleeding or bruising.
Label 7.1: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time (not exceeding normal limits and not producing clinically significant bleeding episodes). The excerpt does not explicitly mention 'fish oil supplements', but it supports an omega-3–class bleeding-time concern.
Patients with kidney or liver disease should use Vascepa with caution and under close medical supervision.
Label 8.7 (hepatic impairment): ALT and AST should be monitored periodically during therapy with VASCEPA. The excerpt does not address kidney disease, but it supports caution/monitoring in hepatic impairment.
Vascepa is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.
Label 4: Contraindicated in patients with known hypersensitivity to VASCEPA or components.
Patients taking Vascepa should inform their healthcare provider of any medications or supplements they are taking.
Label 2.1 and 7.1 emphasize assessing other causes/medications and monitoring with concomitant anticoagulants/antiplatelet agents; the provided excerpt does not state this exact counseling sentence, so support is partial/indirect at best. (Included here only because it aligns with the general label instruction to manage other causes/medications and monitor with concomitant agents.)
Unsupported Statements
Vascepa (icosapent ethyl) is a prescription medication used to lower triglyceride levels in adults with severe hypertriglyceridemia.
Label supports TG reduction in adults with severe (≥500 mg/dL) hypertriglyceridemia (Section 1), but the provided label excerpt does not explicitly state the phrase 'prescription medication' and does not explicitly restrict to 'adults with severe hypertriglyceridemia' for TG lowering as a standalone claim; it is supported as an indication, but the claim is otherwise overly generalized. Marked as partially supported rather than fully unsupported; see omissions/score.
Vascepa works by inhibiting the production of triglycerides in the liver.
Label 12.1 describes multiple potential mechanisms (e.g., reduces hepatic VLDL-TG synthesis and/or secretion; enhances TG clearance; inhibition of DGAT), but 'inhibiting the production of triglycerides' is not the exact phrasing and is broader than the specific 'VLDL-TG synthesis and/or secretion' described in the excerpt.
Vascepa is associated with a reduced risk of pancreatitis and other cardiovascular complications.
Label 1 limitation: effect of VASCEPA on risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. The excerpt does not support 'reduced risk of pancreatitis'. Cardiovascular risk reduction is supported for specified endpoints (Section 1/14.1), but 'other cardiovascular complications' is broader.
Vascepa may increase the risk of hypoglycemia when taken with diabetes medications such as metformin.
No hypoglycemia risk or interaction with metformin is present in the provided label excerpt (Sections 5-7).
Patients taking diabetes medications while using Vascepa should be closely monitored by their healthcare provider.
No diabetes-medication-specific monitoring instruction is present in the provided label excerpt.
Vascepa may increase the risk of muscle damage when taken with statins such as atorvastatin.
No statin-muscle injury risk is stated in the provided label excerpt.
Patients taking statins while using Vascepa should be closely monitored by their healthcare provider.
The provided excerpt supports cardiovascular outcomes trials and bleeding monitoring with antithrombotics, but does not include statin-specific monitoring instructions.
Vascepa may increase the risk of hypotension when taken with blood pressure medications such as lisinopril.
No hypotension or antihypertensive-specific interaction is stated in the provided label excerpt.
Patients taking blood pressure medications while using Vascepa should be closely monitored by their healthcare provider.
No antihypertensive-specific monitoring instruction is present in the provided label excerpt.
Taking Vascepa with vitamin E supplements may increase the risk of bleeding or bruising.
No vitamin E interaction is present in the provided label excerpt.
Taking Vascepa with ginkgo biloba supplements may increase the risk of bleeding or bruising.
No ginkgo biloba interaction is present in the provided label excerpt.
Vascepa is contraindicated in pregnant women.
Label 8.1 Pregnancy describes insufficient data to identify risk; it does not state pregnancy is a contraindication.
Vascepa is contraindicated in breastfeeding mothers.
Label 8.2 Lactation discusses milk detection and lack of infant/milk-production data; it does not state lactation is a contraindication.
Patients with allergies to fish or shellfish should not take Vascepa.
Label 5.2 states it is not known whether patients with fish/shellfish allergies are at increased risk; it advises informing and discontinuing if reactions occur. It does not contraindicate based on fish/shellfish allergy.
Common side effects of Vascepa include gastrointestinal upset, headache, and fatigue.
Provided label excerpt lists common adverse reactions as musculoskeletal pain, peripheral edema, constipation, gout, and atrial fibrillation; it does not include headache, fatigue, or 'gastrointestinal upset' as common adverse reactions in the excerpt.
Patients taking Vascepa should be closely monitored by their healthcare provider.
The label excerpt includes specific monitoring instructions (e.g., bleeding with antithrombotics; ALT/AST in hepatic impairment; monitor for AF/flutter risk). It does not provide a general statement that all patients should be closely monitored without specifying what.
Contradictions
Low
AI Statement
Vascepa is contraindicated in pregnant women.
Label Reference
Label 8.1 Pregnancy: data insufficient to identify risk; no contraindication stated in the provided excerpt.
Low
AI Statement
Vascepa is contraindicated in breastfeeding mothers.
Label Reference
Label 8.2 Lactation: milk detection and lack of data; no contraindication stated in the provided excerpt.
Low
AI Statement
Patients with allergies to fish or shellfish should not take Vascepa.
Label Reference
Label 5.2: not known if increased risk; inform and advise discontinuation if reactions occur; does not state 'should not take'.
Important Omissions
Dosage instructions (4 g/day; dosing frequency; 'with food'; swallow whole; do not break/open/crush/chew) are not provided in the claims list.
Importance:
Moderate
The labeled atrial fibrillation/atrial flutter risk and that incidence is higher in patients with prior history is not mentioned.
Importance:
Moderate
Hepatic impairment monitoring (ALT/AST periodically) is not mentioned.
Importance:
Moderate
Limitation of use regarding pancreatitis risk being 'not determined' is not acknowledged.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Contradictions and unsupported specificity may mislead clinicians/patients: pregnancy and breastfeeding are described as contraindications despite label language not supporting that; fish/shellfish allergy is described as a 'should not take' despite label saying risk is not known and advising counseling/monitoring. Several interaction claims (metformin, statins/muscle damage, lisinopril/hypotension, vitamin E/ginkgo) are not supported by the provided label excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple label-contradicting or unsupported safety statements (pregnancy/breastfeeding contraindications; fish/shellfish allergy absolute avoidance; pancreatitis risk reduction; several drug-specific interaction claims not present in the excerpt).
Suggested Improvement
Restrict statements to the provided label excerpt: use the labeled indications (cardiovascular risk reduction endpoints; severe TG reduction), avoid claiming pancreatitis risk reduction (label says not determined), remove unsupported interaction claims (metformin, atorvastatin/muscle damage, lisinopril/hypotension, vitamin E/ginkgo) unless supported, and replace pregnancy/lactation 'contraindicated' with label-accurate language (insufficient data) and fish/shellfish allergy guidance (unknown increased risk; inform and discontinue if reactions).